Todd Franklin Watanabe, See Remarks at Arcutis Biotherapeutics, Inc. (ARQT), sold 1,200 shares at $17.61 ($21K) on 2025-03-17, disclosed to the SEC on 2025-03-20.
Scheduled sale ($21k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ARQT | SELL | 2025-03-04 | $654K | — | Filing → |
| ARQT | SELL | 2025-02-04 | $490K | — | Filing → |
| ARQT | SELL | 2024-12-23 | $228K | — | Filing → |